| Today's Open | $4.80 |
|---|---|
| Previous Close | $4.82 |
| Daily Range | $4.71 - $4.84 |
| 52-Week Range | $4.19 - $6.95 |
| Market Cap | $867.5M |
| P/E Ratio | -4.92 |
| Dividend (Yield) | $0.00 (0.0%) |
| Volume | 1,023,451 |
| Average Daily Volume | 1,378,865 |
| Current FY EPS | -$1.21 |
Sector
Healthcare
Industry
Drugs
Exelixis (EXEL) Description
A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. Website: http://www.exelixis.com/
News & Commentary
Exelixis Presents COMETRIQ™ (cabozantinib) Clinical Trial Data in Patients with Progressive, Metasta
Exelixis Presents Positive COMETRIQ Clinical Trial Data in Patients with Progressive, Metastatic Med
Exelixis Presents Positive COMETRIQ Clinical Trial Data in Patients with Progressive, Metastatic Medullary Thyroid CancerTackling Cancer: Your Best Investing Ideas
Following three months of examining the 12 most-diagnosed cancers, these stocks look like your best investment choices.Exelixis Present Updated Phase 2 Data for Cabozantinib in Men with Heavily-Pretreated Metastatic Cas
Exelixis Present Updated Phase 2 Data for Cabozantinib in Men with Heavily-Pretreated Metastatic Castration-Resistant Prostate CancerNew Approvals Spark a Melanoma Drug Battle
The FDA approves two of GlaxoSmithKline's new drugs, adding to a new competitive landscapeEXEL's Top Competitors
(-2.07%)
(-0.08%)
(-1.65%)
(-1.80%)